Zacks Research Brokers Reduce Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Investment analysts at Zacks Research cut their Q1 2025 earnings estimates for ACADIA Pharmaceuticals in a research report issued on Tuesday, March 18th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.09 per share for the quarter, down from their prior forecast of $0.14. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.33 EPS, FY2026 earnings at $1.01 EPS and FY2027 earnings at $1.37 EPS.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Stock Down 0.6 %

Shares of ACADIA Pharmaceuticals stock opened at $17.18 on Thursday. The company has a market cap of $2.87 billion, a price-to-earnings ratio of 22.03 and a beta of 0.43. The company’s 50 day moving average is $18.38 and its 200 day moving average is $17.00. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $20.68.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently bought and sold shares of ACAD. Principal Financial Group Inc. grew its stake in ACADIA Pharmaceuticals by 67.8% during the third quarter. Principal Financial Group Inc. now owns 129,551 shares of the biopharmaceutical company’s stock valued at $1,992,000 after acquiring an additional 52,340 shares in the last quarter. Atria Investments Inc grew its stake in ACADIA Pharmaceuticals by 10.8% during the third quarter. Atria Investments Inc now owns 24,437 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 2,384 shares in the last quarter. Victory Capital Management Inc. grew its stake in ACADIA Pharmaceuticals by 2.9% during the third quarter. Victory Capital Management Inc. now owns 97,130 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 2,708 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in ACADIA Pharmaceuticals by 26.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 37,429 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 7,872 shares in the last quarter. Finally, Natixis Advisors LLC grew its stake in ACADIA Pharmaceuticals by 58.6% during the third quarter. Natixis Advisors LLC now owns 40,488 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 14,961 shares in the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now directly owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 6,167 shares of company stock worth $114,583 in the last three months. Company insiders own 28.30% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.